We have a robust drug development pipeline at various clinical and pre-clinical stages.
Note: 1 We own global rights to Plinabulin in all countries except China. In China, we currently own a 60% interest in our Chinese subsidiary, Dalian Wanchunbulin Pharmaceuticals Ltd. ("Wanchunbulin"), which owns a 100% interest in Plinabulin. Wanchunbulin has entered into definitive agreements for the sale of equity interests to certain investors, which are expected to close in the near term. Upon closing, it is expected that we would hold 57.14% of the equity interests in Wanchunbulin.